ArticleArthritis research & therapy2025
Urinary acetylated protein as a biomarker of lupus nephritis: a prospective cohort study.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Transitioning from invasive to liquid biopsy techniques: a bibliometric analysis and prospective insights on biomarkers in lupus nephritis.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveLupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE). Kidney biopsy is the gold standard for diagnosing LN. Post-translational lysine acetylation modifications have emerged as potential biomarkers. This study explored using urinary lysine-acetylated peptides as novel biomarkers for diagnosing LN and assessing activity.
methodsUrine samples were collected from patients with LN (n = 30), SLE without nephritis (n = 30), antineutrophil cytoplasmic antibody-associated glomerulonephritis (AAV-GN; n = 11), and healthy controls (n = 25). The experiment involved two steps: screening through liquid chromatography–mass spectrometry and quantifying five lysine-acetylated peptides through multiple reaction monitoring. Receiver operating characteristic analysis was used to assess the ability of these peptides to differentiate LN from other conditions. Additionally, their diagnostic value for histopathological activity was evaluated.
resultsAmong the five acetylated peptides analyzed, three (ALB-K36, ALB-K161, ALB-K402) were significantly elevated in LN compared to SLE, AAV-GN, and healthy controls. Urinary ALB-K36 exhibited the highest diagnostic accuracy for LN versus AAV-GN (AUC = 0.947). These peptides remained elevated in LN patients with low proteinuria (UPCR < 500 mg/g), suggesting a potential role in early disease detection. Combining ALB-K36 with UPCR improved the diagnostic performance of histological activity index > 2 (AUC = 0.706).
conclusionUrinary lysine-acetylated peptides are promising novel biomarkers for LN diagnosis and histologic assessment, complementing traditional markers, such as UPCR, and highlighting their clinical potential; however, further validation in larger cohorts is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.